

## Request for Proposals (RFP): Janssen Biotech, Inc.

Funding is available to support activities with an enduring component for medical education that is designed to inform healthcare providers about adverse events (AE) that can occur upon treatment of B-cell malignancies with targeted therapies and discuss strategies available for management of these AEs.

**Grant Application Deadline: November 6, 2020**

---

|                              |  |
|------------------------------|--|
| <b>Therapeutic Area:</b>     | B-cell malignancies, specifically chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL)   |
| <b>Treatment Focus:</b>      | Overall learning objectives will focus on education about AEs observed during treatment of CLL/SLL and MCL with targeted therapies and management strategies for addressing these AEs. This will include: <ul style="list-style-type: none"><li>• Discussing the most common and serious AEs that emerge during treatment with specific classes of targeted therapies and available management options</li><li>• Describing the impact on AEs when targeted therapies are combined</li><li>• Addressing specific categories of AEs of clinical interest (eg, cardiovascular events, arthralgias) by creating educational content through collaboration with expert specialists (eg, cardio-oncologists, rheumatologists) as appropriate to provide guidance on management of these AEs</li></ul> |
| <b>Delivery Format:</b>      | Educational programs, meetings series, or conference coverage/symposia with an enduring component  |
| <b>Target Audience:</b>      | Healthcare Providers, Allied Health Professionals, or Advanced Practice Providers  |
| <b>Timelines:</b>            | Program Start Date: By or before Q1 2021   |
| <b>Funding Requirements:</b> | Multi-support programs   |
| <b>Eligibility Criteria:</b> | <u>CME/CE applicants must fall into one of the following categories with a bona fide interest in hematology/oncology or other specialties involved in the management of relevant adverse events:</u><br>Academic institutions (medicine, pharmacy or nursing)<br>Teaching hospitals<br>Medical societies<br>Professional associations<br>Government agencies<br>Medical education companies (accredited)   |
| <b>Submission Link:</b>      | Submissions to Janssen Oncology can be completed online at:<br><a href="https://www.janssen.com/us/grants-and-giving/educational-grants/oncology">https://www.janssen.com/us/grants-and-giving/educational-grants/oncology</a>   |

**Request for Proposals (RFP): Janssen Biotech, Inc.**

**Special Note:**

Due to the ongoing COVID-19 pandemic, it is encouraged that proposals be virtual programs, and proposals for 2021 that may have a live-audience component include contingency plans for virtual delivery.

For any questions related to this RFP, please email [OncologyGrants@its.jnj.com](mailto:OncologyGrants@its.jnj.com).

---